272 filings
DEFA14A
NGNE
Neurogene Inc
26 Apr 24
Additional proxy soliciting materials
2:34pm
ARS
2023 FY
NGNE
Neurogene Inc
26 Apr 24
Annual report to shareholders
2:33pm
DEF 14A
NGNE
Neurogene Inc
Definitive proxy
26 Apr 24
2:33pm
8-K
NGNE
Neurogene Inc
24 Apr 24
Departure of Directors or Certain Officers
5:47pm
8-K
NGNE
Neurogene Inc
22 Apr 24
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
4:44pm
8-K
z5tx92idewg oio8pk
2 Apr 24
Departure of Directors or Certain Officers
3:43pm
8-K
taj62goq0u4z3
18 Mar 24
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
4:10pm
8-K
3ari439g6rjrteue3f3c
4 Mar 24
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett
7:30am
8-K
l5xi b29o7hcl7
21 Feb 24
Departure of Directors or Certain Officers
4:07pm
S-8
0zl5v1oem1l g4
20 Feb 24
Registration of securities for employees
4:16pm
8-K
4i1jjg9
5 Jan 24
Neurogene Announces Business Update and 2024 Outlook
7:11am
8-K
dvl qxeenwvl09u
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
425
azt5ic9 hk15ur1nc99z
6 Dec 23
Business combination disclosure
4:24pm
8-K
n55e 1z7ig7rhoh8n9
6 Dec 23
Other Events
4:21pm
425
g2w6z
4 Dec 23
Business combination disclosure
5:14pm
8-K
53g7z6pdgg9
4 Dec 23
Other Events
5:10pm
425
pxai9awyb
30 Nov 23
Business combination disclosure
4:06pm
EFFECT
ltek4h5o
14 Nov 23
Notice of effectiveness
12:15am